Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Mar 1, 2021

Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the...

Feb 26, 2021

Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its licensing agreement from North Carolina State University ("NC State") to include the...

Feb 25, 2021

Hoth Therapeutics Retains RedChip to Increase Investor Awareness

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its investor relations efforts. RedChip is the leader...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons